Odyssey Therapeutics, Inc. (ODTX) Revenue, Earnings & Financial Statements
$19.37NASDAQ: ODTXMarket Cap $931.07M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Odyssey Therapeutics, Inc. most recently reported annual revenue of $3.0M, a net loss of $149.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$3.0M
Operating Expenses
$164.0M
Operating Profit
−$161.0M
Operating Margin
-5415.2%
Other Income
$12.0M
Interest
$0
Depreciation
$5.0M
Profit Before Tax
−$150.0M
Tax rate (%)
0.6%
Net Profit
−$149.0M
EPS
−$3.15
Quarterly Results — Last 4 Quarters (USD millions)
Metric
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
Operating Expenses
$38.0M
$40.0M
$55.0M
$53.0M
Operating Profit
−$38.0M
−$40.0M
−$55.0M
−$53.0M
Interest
$0
$0
$0
$0
Profit Before Tax
−$35.0M
−$38.0M
−$53.0M
−$53.0M
Tax rate (%)
3.0%
-0.2%
0.0%
-0.1%
Net Profit
−$34.0M
−$38.0M
−$53.0M
−$53.0M
EPS
−$0.70
−$0.80
−$1.10
−$1.11
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$270.0M
Current Assets
$191.0M
Cash
$42.0M
Inventory
$0
Receivables
$0
Fixed Assets
$26.0M
Capital Work in Progress
$0
Investments
$175.0M
Other Assets
$14.0M
Total Liabilities
$758.0M
Current Liabilities
$26.0M
Borrowings
$27.0M
Other Liabilities
$731.0M
Equity
$0
Reserves
−$488.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
−$129.0M
Investing Cash Flow
−$105.0M
Financing Cash Flow
$0
Net Cash Flow
−$17.0M
Free Cash Flow
−$131.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.05
EV / EBITDA
-5.02
FCF Yield
-15.38%
Quick Ratio
12.94
Interest Coverage
-3451.57
Return 1Y
—
Return 3Y
—
Return 5Y
—
Odyssey Therapeutics, Inc. (ODTX) financials — frequently asked questions
What is Odyssey Therapeutics, Inc.'s annual revenue?
Odyssey Therapeutics, Inc. (ODTX) reported annual revenue of $3.0M in its most recent fiscal year.
What is Odyssey Therapeutics, Inc.'s net profit?
Odyssey Therapeutics, Inc. (ODTX) reported a net loss of $149.0M in its most recent fiscal year.
What is ODTX EV/EBITDA?
Odyssey Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -5.02. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks